香港股市 已收市

IQVIA Holdings Inc. (IQV)

NYSE - Nasdaq 即時價格。貨幣為 USD。
加入追蹤清單
224.15+2.01 (+0.91%)
市場開市。 截至 02:32PM EDT。

IQVIA Holdings Inc.

2400 Ellis Road
Durham, NC 27703
United States
919 998 2000
https://www.iqvia.com

版塊Healthcare
行業Diagnostics & Research
全職員工87,000

高階主管

名稱頭銜支付行使價出生年份
Mr. Ari BousbibCEO & Chairman7.15M1961
Mr. Ronald E. BruehlmanExecutive VP & CFO2.14M1961
Mr. Eric M. SherbetExecutive VP, General Counsel & Secretary1.37M1964
Mr. W. Richard Staub IIIPresident of Research & Development Solutions886.44k3.59M1963
Mr. Kevin C. KnightlyPresident of Corporate Strategy & Enterprise Networks1.24M2.81M1961
Ms. Keriann CherofskySenior VP, Corporate Controller & Chief Accounting Officer1985
Mr. Jim BerkshireExecutive Vice President of Global Technology & Operations
Dr. Jeffrey A. Spaeder M.D.Senior VP, Global Chief Medical & Scientific Officer
Kerri JosephSVP of Investment Relation & Treasury
Ms. Trudy SteinChief Human Resources Officer & Executive VP
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

公司管治

截至 2024年5月1日 止,IQVIA Holdings Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中:5;董事會:8;股東權利:7;現金賠償:8。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。